

SAFETY DATA SHEET



Cloprostenol Formulation

Version
12.0

Revision Date:
16.06.2025

SDS Number:
25307-00025

Date of last issue: 03.12.2024
Date of first issue: 24.10.2014

Section 1: Identification

Product name : Cloprostenol Formulation
Other means of identification : ESTRUMATE® (A002698)
ESTRUMATE SYNTHETIC PROSTAGLANDIN FOR CATTLE
AND HORSES (36076)

Manufacturer or supplier's details

Company : MSD
Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand
Telephone : 0800 800 543
Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800
CHEMCALL)
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product
Restrictions on use : Not applicable

Section 2: Hazard identification

GHS Classification

Skin sensitisation : Category 1

GHS label elements

Hazard pictograms : 

Signal word : Warning

Hazard statements : H317 May cause an allergic skin reaction.

Precautionary statements : **Prevention:**
P261 Avoid breathing mist or vapours.
P272 Contaminated work clothing should not be allowed out of the workplace.
P280 Wear protective gloves.

SAFETY DATA SHEET



Cloprostenol Formulation

Version
12.0

Revision Date:
16.06.2025

SDS Number:
25307-00025

Date of last issue: 03.12.2024
Date of first issue: 24.10.2014

Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Benzyl alcohol	100-51-6	>= 1 - < 10
Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate	55028-72-3	< 0.1

Section 4: First-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.

In case of eye contact : Thoroughly clean shoes before reuse.
Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May cause an allergic skin reaction.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

SAFETY DATA SHEET



Cloprostenol Formulation

Version 12.0 Revision Date: 16.06.2025 SDS Number: 25307-00025 Date of last issue: 03.12.2024 Date of first issue: 24.10.2014

Notes to physician : Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

SAFETY DATA SHEET



Cloprostenol Formulation

Version 12.0	Revision Date: 16.06.2025	SDS Number: 25307-00025	Date of last issue: 03.12.2024 Date of first issue: 24.10.2014
-----------------	------------------------------	----------------------------	---

mine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Do not get on skin or clothing. Avoid breathing mist or vapours. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
Conditions for safe storage	: Keep in properly labelled containers. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types: Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate	55028-72-3	TWA	0.01 ug/m3 (OEB 5)	Internal
	Further information: RSEN, Skin			
		Wipe limit	0.1 ug/100 cm ²	Internal

Cloprostenol Formulation

Version 12.0	Revision Date: 16.06.2025	SDS Number: 25307-00025	Date of last issue: 03.12.2024 Date of first issue: 24.10.2014
-----------------	------------------------------	----------------------------	---

Engineering measures

- : The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.
- Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.
- All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
- No open handling permitted.
- Totally enclosed processes and materials transport systems are required.
- Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Organic vapour type
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Section 9: Physical and chemical properties

Appearance	: Aqueous solution
------------	--------------------

Cloprostenol Formulation

Version 12.0	Revision Date: 16.06.2025	SDS Number: 25307-00025	Date of last issue: 03.12.2024 Date of first issue: 24.10.2014
-----------------	------------------------------	----------------------------	---

Colour	:	clear
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	5.6 - 6.1 (20 - 25 °C)
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	1
Density	:	No data available
Solubility(ies)		
Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

SAFETY DATA SHEET



Cloprostenol Formulation

Version
12.0

Revision Date:
16.06.2025

SDS Number:
25307-00025

Date of last issue: 03.12.2024
Date of first issue: 24.10.2014

Molecular weight : No data available

Particle characteristics
Particle size

: Not applicable

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Benzyl alcohol:

Acute oral toxicity : LD50 (Rat): 1,200 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.4 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : Acute toxicity estimate: 1,100 mg/kg
Method: Expert judgement
Remarks: Based on national or regional regulation.

SAFETY DATA SHEET



Cloprostenol Formulation

Version 12.0 Revision Date: 16.06.2025 SDS Number: 25307-00025 Date of last issue: 03.12.2024 Date of first issue: 24.10.2014

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Acute oral toxicity	: LD50 (Rat): > 25 mg/kg Remarks: No mortality observed at this dose.
Acute toxicity (other routes of administration)	: LD50 (Rat): > 50 mg/kg Application Route: Subcutaneous
	: LD50 (Rat): > 50 mg/kg Application Route: Intramuscular
	: LD50 (Rat): 5 mg/kg Application Route: Intravenous Remarks: No mortality observed at this dose.
	: LD50 (Mouse): 350 mg/kg Application Route: Intramuscular
	: LD50 (Mouse): 54.7 mg/kg Application Route: Intravenous
	: TDLo (Monkey): 0.0025 - 0.025 mg/kg Application Route: Intramuscular Target Organs: Lungs Symptoms: Diarrhoea, Vomiting, Rapid respiration
	: TDLo (Monkey): 0.0013 mg/kg Application Route: Intramuscular Target Organs: ovaries

Skin corrosion/irritation

Not classified based on available information.

Components:

Benzyl alcohol:

Species	: Rabbit
Method	: OECD Test Guideline 404
Result	: No skin irritation

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Remarks	: Not classified due to lack of data. Can be absorbed through skin.
---------	--

Serious eye damage/eye irritation

Not classified based on available information.

Cloprostenol FormulationVersion
12.0Revision Date:
16.06.2025SDS Number:
25307-00025Date of last issue: 03.12.2024
Date of first issue: 24.10.2014**Components:****Benzyl alcohol:**

Species	:	Rabbit
Result	:	Irritation to eyes, reversing within 21 days
Method	:	OECD Test Guideline 405
Remarks	:	Not classified due to lack of data.

Respiratory or skin sensitisation**Skin sensitisation**

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:**Benzyl alcohol:**

Test Type	:	Human repeat insult patch test (HRIPT)
Exposure routes	:	Skin contact
Species	:	Humans
Result	:	positive
Assessment	:	Probability or evidence of low to moderate skin sensitisation rate in humans

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Result	:	Sensitiser
--------	---	------------

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Benzyl alcohol:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative

SAFETY DATA SHEET



Cloprostenol Formulation

Version 12.0 Revision Date: 16.06.2025 SDS Number: 25307-00025 Date of last issue: 03.12.2024 Date of first issue: 24.10.2014

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: In vitro mammalian cell gene mutation test Test system: mouse lymphoma cells Result: negative
	Test Type: Chromosomal aberration Test system: Human lymphocytes Result: equivocal
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Intraperitoneal Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Benzyl alcohol:

Species	: Mouse
Application Route	: Ingestion
Exposure time	: 103 weeks
Method	: OECD Test Guideline 451
Result	: negative

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Remarks	: Not classified due to lack of data.
---------	---------------------------------------

Reproductive toxicity

Not classified based on available information.

Components:

Benzyl alcohol:

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials
Effects on foetal development	: Test Type: Embryo-foetal development Species: Mouse Application Route: Ingestion Result: negative

SAFETY DATA SHEET



Cloprostenol Formulation

Version 12.0 Revision Date: 16.06.2025 SDS Number: 25307-00025 Date of last issue: 03.12.2024 Date of first issue: 24.10.2014

||

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Effects on fertility	: Test Type: Three-generation study Species: Rat Application Route: Oral General Toxicity F1: NOAEL: 0.015 mg/kg body weight Fertility: NOAEL: > 0.04 mg/kg body weight Result: Animal testing did not show any effects on fertility.
	Species: Cattle Application Route: Intramuscular General Toxicity - Parent: LOAEL: 0.16 µg/kg Result: positive Remarks: Abortion
Effects on foetal development	: Test Type: Development Species: Rabbit Application Route: Subcutaneous Teratogenicity: NOAEL: 0.250 µg/kg Result: No teratogenic effects
	Test Type: Development Species: Rat Application Route: Oral Teratogenicity: NOAEL: 100 µg/kg Result: No teratogenic effects
Reproductive toxicity - Assessment	: May damage fertility.

STOT - single exposure

Not classified based on available information.

Components:

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Target Organs	: Lungs
Assessment	: Causes damage to organs.

STOT - repeated exposure

Not classified based on available information.

Components:

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Target Organs	: Ovary
Assessment	: Causes damage to organs through prolonged or repeated exposure.

SAFETY DATA SHEET



Cloprostenol Formulation

Version
12.0

Revision Date:
16.06.2025

SDS Number:
25307-00025

Date of last issue: 03.12.2024
Date of first issue: 24.10.2014

Repeated dose toxicity

Components:

Benzyl alcohol:

Species	:	Rat
NOAEL	:	1.072 mg/l
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	28 Days
Method	:	OECD Test Guideline 412

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Species	:	Rat
NOAEL	:	0.05 mg/kg
LOAEL	:	0.15 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Ovary

Species	:	Rat
LOAEL	:	0.0125 mg/kg
Application Route	:	Subcutaneous
Exposure time	:	30 Days
Target Organs	:	Ovary

Species	:	Monkey
NOAEL	:	0.05 mg/kg
LOAEL	:	0.15 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Heart, Testis

Aspiration toxicity

Not classified based on available information.

Components:

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Not applicable

Experience with human exposure

Components:

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

General Information	:	Target Organs: Uterus (including cervix) Symptoms: Embryo-foetal toxicity, foetal mortality, menstrual irregularities, miscarriage
---------------------	---	---

SAFETY DATA SHEET



Cloprostenol Formulation

Version
12.0

Revision Date:
16.06.2025

SDS Number:
25307-00025

Date of last issue: 03.12.2024
Date of first issue: 24.10.2014

Inhalation	Target Organs: Lungs Symptoms: Asthma, bronchospasm
	: Target Organs: Lungs Symptoms: bronchospasm, Asthma Remarks: May cause sensitisation of susceptible persons by inhalation of aerosol or dust. Target Organs: Uterus (including cervix) Symptoms: Embryolethal effects, menstrual irregularities
Skin contact	: Target Organs: Lungs Symptoms: bronchospasm Remarks: Can be absorbed through skin. Target Organs: Uterus (including cervix) Symptoms: Embryolethal effects

Section 12: Ecological information

Ecotoxicity

Components:

Benzyl alcohol:

Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): 460 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 230 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): 770 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 310 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 51 mg/l Exposure time: 21 d Method: OECD Test Guideline 211

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Ecotoxicology Assessment

Acute aquatic toxicity	: Toxic effects cannot be excluded
Chronic aquatic toxicity	: Toxic effects cannot be excluded

Cloprostenol FormulationVersion
12.0Revision Date:
16.06.2025SDS Number:
25307-00025Date of last issue: 03.12.2024
Date of first issue: 24.10.2014**Persistence and degradability****Components:****Benzyl alcohol:**

Biodegradability : Result: Readily biodegradable.
Biodegradation: 92 - 96 %
Exposure time: 14 d

Bioaccumulative potential**Components:****Benzyl alcohol:**

Partition coefficient: n-octanol/water : log Pow: 1.05

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

SAFETY DATA SHEET



Cloprostenol Formulation

Version 12.0 Revision Date: 16.06.2025 SDS Number: 25307-00025 Date of last issue: 03.12.2024
Date of first issue: 24.10.2014

Packing instruction (cargo aircraft) : Not applicable

Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

NZS 5433

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Hazchem Code : Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number

HSR100759 Veterinary Medicines Non dispersive Open System Application Group Standard

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS : not determined

Cloprostenol Formulation

Version 12.0	Revision Date: 16.06.2025	SDS Number: 25307-00025	Date of last issue: 03.12.2024 Date of first issue: 24.10.2014
-----------------	------------------------------	----------------------------	---

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 16.06.2025

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

SAFETY DATA SHEET



Cloprostenol Formulation

Version
12.0

Revision Date:
16.06.2025

SDS Number:
25307-00025

Date of last issue: 03.12.2024
Date of first issue: 24.10.2014

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN